Carmen Criscitiello· @CarmenCriscit · X·· 1 天前评分70
正文 · 机器翻译
很高兴看到我的老友 @antgiorda 在 #ESMO26 上介绍 FOURLIGHT-1：atirmociclib + fulvestrant 在既往接受 CDK4/6 治疗后改善了 PFS，相比研究者选择方案（9.4 vs 6.6 个月，HR 0.60）。CDK4/6 治疗后的数据令人鼓舞。#ESMOAmbassadors @myESMO
98 浏览 · 6 赞 · 1 转发 · 0 回复
会议摘要
1842O按 Proffered paper 2: Breast cancer, early and advanced stage 对上
Efficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)
https://esmocongress.esmo.orgFOURLIGHT-1
https://esmocongress.esmo.org来源：Carmen Criscitiello · x.com